Group 1 - Company subsidiary Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.49 million yuan and late fees of about 10.74 million yuan, while Hainan Kangli Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.28 million yuan and late fees of about 11.71 million yuan, totaling around 65.22 million yuan [1][2] - The tax payment does not involve any administrative penalties and will be settled as required [1] - The tax arrears and late fees will be included in the company's 2025 profit and loss, expected to impact the net profit by 65.22 million yuan [2] Group 2 - Company subsidiary Tianfang Pharmaceutical Co., Ltd. received approval for the drug Clarithromycin Tablets, which passed the consistency evaluation for generic drug quality and efficacy [4][5] - Clarithromycin is used to treat infections caused by sensitive pathogens, with a market presence since 1991 [5][8] - The total investment in the Clarithromycin project is approximately 11.79 million yuan [7] - The domestic sales of Clarithromycin in public hospitals and grassroots medical institutions were about 407 million yuan in 2024, with the company's sales at approximately 2.83 million yuan [8]

Group 1 - Huawei's rotating chairman Meng Wanzhou emphasizes the importance of resilience and professionalism in overcoming challenges and creating value in the face of the intelligent transformation wave, highlighting the need for strategic focus and organizational strength by 2026 [27] - Hengrui Medicine plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, aiming to address unmet clinical needs and enhance international cooperation for global commercialization of Chinese innovative drugs by 2026 [28] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials, to create a competitive advantage and develop an integrated growth model by 2026 [29] Group 2 - Muyuan Foods' chairman Qin Yinglin reflects on the company's journey from starting with 22 pigs to becoming the largest pig farming enterprise globally, emphasizing the importance of innovation and technology in achieving a dignified and efficient pig farming process by 2026 [30] - Gree Electric's chairman Dong Mingzhu commits to deepening core business and accelerating in smart equipment and new energy sectors, while focusing on green and digital transformation to enhance product quality and service for global users by 2026 [31] - Geely Holding Group's chairman Li Shufu highlights the importance of making bold decisions during critical moments, emphasizing the need to overcome challenges and maintain core values as the company approaches its 40th anniversary in 2026 [32] Group 3 - SAIC Motor's chairman Wang Xiaoqiu outlines the company's commitment to deepening reforms and focusing on intelligent and electric vehicle development, aiming for high-quality growth and user-centered innovation by 2026 [32] - Hengli Group's chairman Chen Jianhua stresses the importance of practical action and innovation in overcoming development challenges, encouraging a proactive approach to seize opportunities in the coming years [33] - LONGi Green Energy's chairman Zhong Baoshan believes the photovoltaic industry is at a pivotal moment, emphasizing the need for technological innovation to navigate challenges and capitalize on the global green energy transition [34] Group 4 - Inspur's chairman Li Jun emphasizes the transformative impact of artificial intelligence on the global economy and the importance of open collaboration to unlock AI's potential, with a focus on building a comprehensive innovation ecosystem by 2026 [35] - TCL's chairman Li Dongsheng highlights the need for strategic focus on achieving global leadership and enhancing core capabilities to drive high-quality development amid economic uncertainties in 2026 [36] - Trina Solar's co-chairman Gao Haichun emphasizes the company's evolution from a product supplier to a system-level innovator, focusing on creating solutions that transcend traditional competition by 2026 [38] Group 5 - JinkoSolar's chairman Li Xian-de discusses the potential of space photovoltaic technology as a sustainable energy solution for future AI power needs, marking the company's 20th anniversary with a vision for universal solar energy [39] - Leo Group's chairman Wang Xiangrong aims to enhance the company's strategic focus and sustainable value, emphasizing collaboration with customers and employees to achieve higher-dimensional value creation by 2026 [40] - Innovent Biologics' chairman Cui Jisong outlines the company's commitment to innovation and global expansion, aiming to launch multiple new drugs and maintain an entrepreneurial spirit in the face of uncertainty by 2026 [41]

Group 1 - Huawei's rotating chairman Meng Wanzhou emphasized the importance of resilience and professionalism in overcoming challenges and creating value, highlighting the long-term strategic opportunities presented by the wave of intelligent transformation [25] - Hengrui Medicine's chairman Sun Piaoyang announced plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, while promoting international cooperation and accelerating overseas clinical trials [26] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials [27] Group 2 - Muyuan Foods' chairman Qin Yinglin expressed commitment to smart pig farming and improving animal health, aiming to enhance the quality and safety of pork for consumers [28] - Gree Electric's chairman Dong Mingzhu plans to deepen the core business while accelerating in smart equipment and renewable energy sectors, emphasizing a commitment to green and digital transformation [29] - Geely Holding Group's chairman Li Shufu highlighted the importance of making bold decisions during critical moments, focusing on core values and sustainable development [30] Group 3 - SAIC Motor's chairman Wang Xiaoqiu stated the company will deepen reforms and focus on intelligent and electric vehicle development, aiming for high-quality growth [30] - Hengli Group's chairman Chen Jianhua emphasized the need for a proactive approach to overcome challenges and achieve breakthroughs in the coming years [31] - LONGi Green Energy's chairman Zhong Baoshen believes the photovoltaic industry is at a pivotal moment, with significant opportunities for innovation and growth [32] Group 4 - TCL's chairman Li Dongsheng stressed the importance of maintaining strategic focus and enhancing core capabilities to achieve high-quality development [33] - Inspur's acting chairman Li Jun highlighted the transformative impact of artificial intelligence on the economy and the need for open and collaborative innovation [35] - Trina Solar's co-chairman Gao Haichun mentioned the company's evolution from a product supplier to a solution provider, focusing on system-level product innovation [36] Group 5 - JinkoSolar's chairman Li Xian-de discussed the potential of space photovoltaic technology as a sustainable energy solution for future challenges [37] - LEO Technology's chairman Wang Xiangrong emphasized the importance of creating value beyond mere data growth, focusing on sustainable and collaborative progress [38] - Innovent Biologics' chairman Cui Jisong outlined the company's commitment to innovation and global expansion in the next decade [39] Group 6 - Fosun International's chairman Guo Guangchang highlighted the growing demand for health and wellness, emphasizing the need to leverage the company's strengths in various industries [40] - Obsidian Technology's chairman Huang Yuanhao expressed the importance of innovation in robotics and AI vision, aiming to lead in the upcoming technological revolution [41] - Volkswagen's chairman Yang Guoping emphasized the commitment to brand and innovation as the company embarks on a new journey in the "14th Five-Year Plan" [42]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

（编辑：曹学平 审核：童海华 校对：翟军） 中国医药方面表示，上述补缴税款和滞纳金将计入公司2025年当期损益，预计影响公司2025年度净利润 6521.78万元。 中国医药业务主要分为医药工业、医药商业、国际贸易、大健康和电商等。2025年前三季度，中国医药 累计实现营业收入258.94亿元，同比下降3.42%；实现归属于上市公司股东的净利润为4.55亿元，同比 下降4.64%。此次两家子公司补缴税款预计将对中国医药全年业绩造成一定影响。 中经记者 晏国文 卢志坤 北京报道 2026年1月1日，中国医药（600056.SH）披露，下属全资子公司海南通用三洋药业有限公司（以下简 称"三洋药业"）和海南康力药业有限公司（以下简称"康力药业"）分别收到国家税务总局海口市税务局 第一税务分局关于要求补缴相关税款的《税务事项通知书》。 三洋药业需补缴税款2148.62万元，滞纳金约为1074.29万元；康力药业需补缴税款2128.26万元，滞纳金 约为1170.61万元。两家子公司合计需补缴税款及滞纳金约6521.78万元。 ...

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1: Mergers and Acquisitions - Haili Biological's subsidiary, Ruisheng Biological, plans to invest 61.2 million yuan to acquire 51% equity in seven dental chain companies located in Yangzhou and Changzhou, which is expected to increase the company's revenue by approximately 100 million yuan and net profit by over 7 million yuan [1] - Yanggu Huatai has decided to terminate the issuance of shares and cash payment to acquire 99.64% equity in Bomi Technology, opting to negotiate for partial equity acquisition in cash instead [2] - Yachuang Electronics intends to issue shares and pay cash totaling 317 million yuan to purchase 40% equity in Shenzhen Ouchuang Semiconductor and 45% equity in Shenzhen Yihai Nengda, constituting a major asset restructuring [3] Group 2: Earnings Forecasts - Guangku Technology anticipates a net profit attributable to shareholders of 169 million to 182 million yuan for 2025, representing a year-on-year growth of 152% to 172% [4] Group 3: Shareholding Changes - Jianzhijia's actual controller, Yunnan Xiangqun, plans to increase its stake in the company by up to 2% through a concentrated bidding process, with an investment amount of 50 million yuan sourced from its own funds and a loan of up to 45 million yuan from CITIC Bank [5] - Zhenzhong Investment, a significant shareholder of Lvdiaofeng, plans to reduce its stake by no more than 1% through a concentrated bidding process, equating to a maximum of 680,000 shares [6] - Two shareholders of Lingzhi Software plan to reduce their holdings by a combined total of up to 1.43%, with one shareholder reducing by up to 3.281 million shares (0.82% of total shares) and the other by up to 2.4492 million shares (0.61% of total shares) [7] Group 4: Tax Issues - Tianyue Advanced announced that it needs to pay a total of 82.9728 million yuan in corporate income tax and late fees, which will be recorded in the 2025 financial results, expected to reduce the company's net profit for that year [8] - China Pharmaceutical's wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical and Hainan Kangli Pharmaceutical, received tax notices requiring a total payment of approximately 65.2178 million yuan in taxes and late fees, which will also impact the company's net profit for 2025 [9][10] Group 5: Regulatory Issues - Platelite has received a notice from the China Securities Regulatory Commission regarding a case of suspected illegal information disclosure, leading to an official investigation [11] Group 6: Legal Matters - Baotailong announced that its subsidiary, Shuangyashan Longmei Tiantai Coal Chemical Co., is involved in a significant lawsuit that has entered the second instance, with a ruling requiring it to pay 316 million yuan in contract price and interest, while also receiving compensation and a return of a quality guarantee deposit [12]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for Tianfang Pharmaceutical, enhancing its product portfolio [1] - Clarithromycin Tablets are now positioned to compete in the market following the successful evaluation [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical sector [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval notification for Clarithromycin Tablets was issued by the National Medical Products Administration [1] - The drug has successfully passed the consistency evaluation of quality and efficacy, indicating its compliance with regulatory standards [1]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-001 号 中国医药健康产业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 通知书编号：2025B06253 剂型：片剂 规格：0.25g 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的克拉霉素片（以下简称"该药品"）《药品补 充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。现将有关情况 公告如下： 一、通知书基本信息 药品名称：克拉霉素片 受理号：CYHB2450415 经查询国家药监局网站显示，截至本公告披露日，除天方药业外，国内已有 浙江贝得药业有限公司、石药集团欧意药业有限公司、宜昌东阳光长江药业股份 有限公司、西安利君制药有限责任公司等 10 多家企业通过或视同通过该药品的 一致性评价。 注册分类：化学药品 上市许可持有人：天方药业有限公司 审批结论：根据《中华人 ...